上海博爱方本（苏州）律师事务所 关于苏州敏芯微电子技术股份有限公司 法律意见书 中国江苏省苏州市苏州工业园区圆融时代广场 24 幢苏州国寿金融中心 401 室 上海博爱方本（苏州）律师事务所 关于苏州敏芯微电子技术股份有限公司 法律意见书 致：苏州敏芯微电子技术股份有限公司 上海博爱方本（苏州）律师事务所（以下简称"本所"）接受苏州敏芯微电子 技术股份有限公司（以下简称"敏芯股份"或"公司"）的委托，指派本所律师出席 公司于 2025 年 5 月 16 日召开的 2024 年年度股东大会（以下简称"本次股东大 会"），并根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）和《上市公司股东大会规则》（以 下简称"《股东大会规则》")等有关法律、法规和规范性文件以及《苏州敏芯微 电子技术股份有限公司章程》（以下简称"《公司章程》"）的规定和要求，按照 律师行业公认的业务标准、道德规范和勤勉尽责精神，出具本法律意见书。 为出具本法律意见书，本所律师查验了公司提供的有关公司召开本次股东大 会的文件，同时听取了公司就有关事实的陈述和说明，出席了本次股东大会。 本法 ...

Group 1 - The company completed the election of independent directors, nominating Liu Wen, Wang Meiqi, and Lu Zhenghao as candidates, with Wang Meiqi being a professional accountant [1][2] - The term for the newly elected independent directors will last until the end of the current board's term [1] - The company expressed gratitude to the outgoing independent directors, Li Shuxi, Wang Mingxiang, and Yang Zhenchuan, for their contributions during their tenure [2] Group 2 - The company adjusted the members of its specialized committees during the seventh board meeting, with changes in the Strategic Decision Committee, Nomination Committee, Audit Committee, and Remuneration and Assessment Committee [2] - The adjustments were made to ensure the smooth operation of the specialized committees under the fourth board [2] - The new committee members' terms will also last until the end of the current board's term [2]

证券代码：688286 证券简称：敏芯股份 公告编号：2025-037 苏州敏芯微电子技术股份有限公司 关于完成独立董事补选及调整董事会专门委员会委 员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、补选独立董事的情况 苏州敏芯微电子技术股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第四届董事会第五次会议，审议通过了《关于补选公司第四届董事会独立 董事的议案》，公司董事会同意提名刘雯女士、王美琪女士、鲁征浩先生为公司 第四届董事会独立董事候选人，其中王美琪女士为会计专业人士，任期自股东大 会审议通过之日起至第四届董事会任期届满之日止。具体内容详见公司于 2025 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露的《关于补选独立 董事的公告》（公告编号：2025-032）。 2025 年 5 月 16 日，公司召开了 2024 年年度股东大会，补选刘雯女士、王 美琪女士、鲁征浩先生为公司第四届董事会独立董事，任期自本次股东大会审议 通过之日起至第四届董事会届满之 ...

关于苏州敏芯微电子技术股份有限公司 2024 年年度股东大会的 法律意见书 中国江苏省苏州市苏州工业园区圆融时代广场 24 幢苏州国寿金融中心 401 室 上海博爱方本（苏州）律师事务所 本法律意见书仅供公司为本次股东大会之目的而使用，不得被任何人用于其 他任何目的。本所同意，公司可以将本法律意见书作为公司本次股东大会公告材 料，随其他需要公告的信息一起向公众披露。 2 一、本次股东大会召集、召开的程序 上海博爱方本（苏州）律师事务所 关于苏州敏芯微电子技术股份有限公司 2024 年年度股东大会的 法律意见书 致：苏州敏芯微电子技术股份有限公司 上海博爱方本（苏州）律师事务所（以下简称"本所"）接受苏州敏芯微电子 技术股份有限公司（以下简称"敏芯股份"或"公司"）的委托，指派本所律师出席 公司于 2025 年 5 月 16 日召开的 2024 年年度股东大会（以下简称"本次股东大 会"），并根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）和《上市公司股东大会规则》（以 下简称"《股东大会规则》")等有关法律、法规和规范性文件以及《苏州敏芯微 电子技术 ...

证券代码：688286 证券简称：敏芯股份 公告编号：2025-038 苏州敏芯微电子技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：中国（江苏）自由贸易试验区苏州片区苏州工业 园区旺家浜巷 8 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 32 | | --- | --- | | 普通股股东人数 | 32 | | 2、出席会议的股东所持有的表决权数量 | 18,021,857 | | 普通股股东所持有表决权数量 | 18,021,857 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.5720 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32 ...

2024 年年度股东大会会议资料 证券代码：688286 证券简称：敏芯股份 苏州敏芯微电子技术股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 - 1 - 2024 年年度股东大会会议资料 | 2024 年年度股东大会会议须知 3 | | --- | | 年年度股东大会会议议程 5 2024 | | 2024 年年度股东大会会议议案 7 | | 议案一：《关于<公司 2024 年年度报告及其摘要>的议案》 7 | | 议案二：《关于<公司 年度董事会工作报告>的议案》 8 2024 | | 议案三：《关于<公司 2024 年度监事会工作报告>的议案》 17 | | 议案四：《关于<公司 2024 年度利润分配方案>的议案》 22 | | 议案五：《关于<公司 年度财务决算报告>的议案》 2024 23 | | 议案六：《关于<公司 2024 年度独立董事述职报告>的议案》 29 | | 议案七：《关于<公司 2025 年度董事薪酬方案>的议案》 30 | | 议案八：《关于<公司 2025 年度监事薪酬方案>的议案》 31 | | 议案九：《关于公司及子公司向银行申请综合授信额度并提供担保的 ...

Investment Rating - The investment rating for the company is upgraded to "Buy" due to strong performance of new products and anticipated demand from AI applications [4][6]. Core Views - The company achieved a revenue of 506 million yuan in 2024, representing a year-on-year increase of 35.71%, and a net profit attributable to shareholders of -35.24 million yuan, a reduction in loss by 67 million yuan [1][4]. - The fourth quarter of 2024 saw a significant turnaround with a revenue of 169 million yuan, a year-on-year growth of 48.86%, and a net profit of 13 million yuan, marking a return to profitability [1][2]. - The company has made substantial progress in the pressure sensor business, with its revenue share increasing to 41.85%, up by 19.19 percentage points from the previous year [2][3]. Financial Performance - The company reported a comprehensive gross profit margin increase of 8.07 percentage points year-on-year, indicating a recovery in product profitability [2]. - Research and development expenses for 2024 were 80.97 million yuan, a 3.93% increase from the previous year, with 201 R&D personnel accounting for 33.06% of the total workforce [3]. - The company forecasts a net profit of 38.43 million yuan for 2025 and 66.16 million yuan for 2026, with a new estimate of 180 million yuan for 2027 [4][11]. Market Position and Strategy - The company is focusing on technological innovation and has made significant investments in R&D, particularly in AI-related products such as MEMS acoustic sensors and digital microphones [3]. - The product structure is continuously optimized, transitioning from a single product focus to a multi-product line strategy, enhancing its market position as a platform company based on MEMS technology [2][3]. - The company has initiated a share buyback program, repurchasing 425,399 shares, which represents 0.76% of the total share capital, to maintain investor interests [4].

Investment Rating - The investment rating for the company is upgraded to "Buy" due to strong performance of new products and anticipated demand from AI applications [4][6][17] Core Viewpoints - The company achieved a revenue of 506 million yuan in 2024, representing a year-on-year increase of 35.71%, and turned a profit in Q4 2024 with a net profit of 13 million yuan [1][2] - The pressure sensor business saw significant breakthroughs, with its revenue share rising to 41.85%, an increase of 19.19 percentage points year-on-year, indicating a successful transition to a multi-product line strategy [2][3] - The company continues to invest in R&D, with expenses reaching 80.97 million yuan in 2024, a 3.93% increase from the previous year, and a focus on developing new AI-related products [3][4] Financial Performance Summary - In 2024, the company reported a total revenue of 506.74 million yuan, with a growth rate of 35.71% compared to 2023 [5][11] - The EBITDA for 2024 was 112.72 million yuan, with a projected EBITDA of 91.59 million yuan for 2025 [5][11] - The net profit attributable to the parent company for 2024 was a loss of 35.24 million yuan, with forecasts of a profit of 38.43 million yuan in 2025 and 66.16 million yuan in 2026 [5][11] Market and Product Development - The company is focusing on the consumer electronics market, particularly the smartphone sector, which is showing improved demand [2] - New AI-related products, such as high signal-to-noise ratio digital microphones, are under development, with expectations for rapid growth in the AI sector [3][4] - The company has initiated a share buyback program, repurchasing 425,399 shares to enhance shareholder value [4]

Group 1 - The core products of Zhaoli Pharmaceutical show stable growth, with a high dividend payout ratio maintained, achieving a revenue of 2.578 billion yuan in 2024, a year-on-year increase of 32.71% [8][9] - The company has significantly reduced costs and improved efficiency, with a notable decrease in expense ratios, including a sales expense ratio of 32.53%, down 7.5 percentage points year-on-year [9] - The company plans to implement an employee stock ownership plan by the end of 2024, with profit growth targets set at no less than 30% for 2025 [10] Group 2 - Weining Health's revenue for Q1 2025 was 345 million yuan, a year-on-year decrease of 30.24%, with a net profit of 5.29 million yuan, down 68.18% [11][12] - The company is focusing on cost reduction and efficiency improvement, with a significant increase in cash flow from operating activities, up 120.53% year-on-year [12] - The WiNEX product is entering a phase of mass delivery, supporting internet operations and international adaptation, with a strong digital architecture capable of handling millions of transactions [14][15] Group 3 - Lais Information's revenue for 2024 was 1.61 billion yuan, a year-on-year decrease of 3.94%, while Q1 2025 revenue dropped by 55.53% to 109 million yuan [17][18] - The company is optimizing its business structure, with significant growth in air traffic control and urban traffic management sectors, achieving revenue increases of 13.68% and 33.47% respectively [18][19] - The company is enhancing its research and development efforts, with a focus on refining its product offerings and improving operational efficiency [20] Group 4 - FenJung Media reported a revenue of 12.262 billion yuan in 2024, a year-on-year increase of 3.01%, with a net profit of 5.155 billion yuan, up 6.80% [23][25] - The company maintains a high dividend payout ratio, with cash dividends amounting to 4.766 billion yuan, representing 92.45% of net profit [24][25] - The planned acquisition of New潮传媒 is expected to enhance the company's competitive position in the outdoor advertising market [28] Group 5 - Jingwang Electronics achieved a revenue of 12.659 billion yuan in 2024, a year-on-year increase of 17.68%, with a net profit of 1.169 billion yuan, up 24.86% [30][31] - The company is expanding its production capacity, with a focus on high-end markets and AI applications, particularly in the automotive sector [32][33] - The company is increasing its R&D investments to support technological advancements and market expansion [33]

Financial Performance - The company's revenue for Q1 2025 reached ¥134,962,790.04, representing a 53.05% increase compared to ¥88,183,289.62 in the same period last year[4] - Net profit attributable to shareholders was ¥2,848,652.80, a turnaround from a loss of ¥14,446,483.54 in the previous year[4] - The net cash flow from operating activities improved to ¥1,911,732.36, recovering from a negative cash flow of ¥31,122,293.18 in the prior year[4] - Operating profit for Q1 2025 was ¥2,869,177.29, recovering from a loss of ¥14,668,570.28 in Q1 2024[20] - Net profit for Q1 2025 was ¥2,780,434.85, compared to a net loss of ¥14,664,434.36 in the same period last year[21] - The company's total equity increased to ¥1,032,173,043.64 in Q1 2025, up from ¥1,028,379,236.19 in Q1 2024[20] Earnings and Margins - The basic earnings per share increased to ¥0.05, compared to a loss of ¥0.26 per share in the same period last year[4] - Basic earnings per share for Q1 2025 was ¥0.05, compared to a loss per share of ¥0.26 in Q1 2024[21] - The weighted average return on equity improved to 0.28%, an increase of 1.64 percentage points from -1.36% in the previous year[4] - The net profit attributable to shareholders increased by ¥1,729.51 million, driven by higher sales and improved gross margin[9] Cash Flow and Liquidity - The company reported a net increase of ¥3,303.40 million in cash flow from operating activities, primarily due to profit growth and inventory procurement[9] - Cash inflow from operating activities totaled ¥176,223,539.76 in Q1 2025, compared to ¥121,839,359.10 in Q1 2024, marking an increase of 44.7%[23] - The net cash flow from investing activities was $10,111,890.58, compared to a negative cash flow of $58,430,119.96 in the previous period[24] - The ending balance of cash and cash equivalents was $155,928,180.14, up from $139,423,521.69 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,198,646,770.94, a slight decrease of 1.01% from ¥1,210,873,724.91 at the end of the previous year[5] - Total current assets as of March 31, 2025, amount to ¥660,646,277.69, an increase from ¥645,563,445.92 as of December 31, 2024[15] - Total liabilities decreased to ¥166,473,727.30 in the latest quarter from ¥182,494,488.72 in the previous year, a reduction of 8.8%[20] - Total non-current assets decreased to ¥538,000,493.25 from ¥565,310,278.99[16] Research and Development - Research and development expenses totaled ¥16,712,765.83, accounting for 12.38% of revenue, down from 21.88% in the previous year, reflecting a decrease of 9.50 percentage points[5] - Research and development expenses decreased to ¥16,712,765.83 in Q1 2025 from ¥19,294,153.27 in Q1 2024, reflecting a reduction of 13.4%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,021[11] - The largest shareholder, Li Gang, holds 10,745,026 shares, representing 19.19% of total shares[11] Other Financial Activities - The company did not apply new accounting standards starting from 2025[25] - The company received $20,000,000.00 in cash from borrowings during the financing activities[24] - Cash paid for debt repayment was $400,000.00, while cash paid for dividends and interest was $271,946.61[24] - The impact of exchange rate changes on cash and cash equivalents was -$8,446.06[24] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[13]